Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biotherapeutics

John Watson's Biography



John Watson, Director, Promega Corporation

Dr. Watson has a B.S. in Genetics and Cell Biology from the University of Minnesota, an M.S. in Bacteriology; and a Ph.D. in Biomolecular Chemistry from the University of Wisconsin. After a clinical postdoctoral fellowship in Clinical Chemistry and Molecular Diagnostics he became Director of Molecular Diagnostics at Epicentre Technologies where he led R&D and Marketing efforts for their clinical products. Subsequent positions have included Director of Cellular Analysis at Promega Corporation, and Director of Marketing for the PanVera division Vertex Pharmaceuticals (becoming Director of Marketing for Drug Screening at Invitrogen after the acquisition). He also managed R&D, applications and Marketing for the FTIR instrument division of Thermo Electron Corporation.

John Watson Image

Development of a Bioluminescent Cell-based Bioassay to Measure Fc Effector Functionality in Antibody-dependent Cellular Cytotoxicity

Thursday, 28 June 2012 at 14:45

Add to Calendar ▼2012-06-28 14:45:002012-06-28 15:45:00Europe/LondonTitle to be ConfirmedSELECTBIOenquiries@selectbiosciences.com

We have developed an alternative cell-based bioassay that can be used to quantify potency of Fc effector function of monoclonal antibodies bound to target cells.  The assay is a thaw-and-use bioluminescent NFAT-RE-luciferase reporter bioassay.which differentiates between antibodies with small differences in glycosylation that affects Fc effector activity in ADCC.


Add to Calendar ▼2012-06-27 00:00:002012-06-28 00:00:00Europe/LondonBiotherapeuticsSELECTBIOenquiries@selectbiosciences.com